Oxidatively modified low-density lipoprotein (OxLDL) is present in atherosclerotic lesions and has been proposed to play an important role in atherogenesis as an atherogenic lipoprotein in vivo. 1) OxLDL is known to have various atherogenic effects, e.g. acting as a chemoattractant for circulating monocytes, 2) impairing endothelium-dependent arterial relaxation, 3) and being cytotoxic to endothelial cells. 4) In addition, OxLDL is also known to promote the initiation of coagulation by enhancing the expression of tissue factor 5) and OxLDL also mitigates anticoagulant mechanisms such as thrombomodulin-dependent protein C activation 6) and the expression of tissue factor pathway inhibitor. 7) Human atherosclerosis involves 2 distinct pathologic processes-conventional atherogenesis at early stages, and atherothrombosis at advanced stages, which is responsible for acute manifestations of the disease. 8, 9) Atherogenesis is initiated by oxidation of LDL and recruitment of monocytes to the intima of the vessel wall leading to accumulation of OxLDL in macrophages and smooth muscle cells (SMCs) and their transformation into lipid-laden foam cells. 9) This process is accompanied by extensive cell proliferation and elaboration of extracellular matrix components accounting for atheroma progression. 10) However, severe clinical complications of atherosclerosis, including myocardial infarction, ischemic stroke, and sudden cardiac death, are caused by atherothrombosis manifested in thrombus formation primarily on ruptured advanced atherosclerotic plaques, which finally leads to occlusion of the vessel lumen. 11, 12) A major role in determining thrombogenicity of human atherosclerotic lesions has been ascribed to the extrinsic, tissue factordependent pathway of blood coagulation. 13) Recently, Ananyeva et al. revealed that the exposure of macrophages and SMCs to OxLDL significantly enhanced their ability to support activity of 2 major complexes of the intrinsic pathway of blood coagulation, the Xase and prothrombinase, and suggested that the intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaques. 14) In addition, Saenko et al. demonstrated that Xase activity is stimulated with OxLDL, 15) and Blann et al. reported that OxLDL induced the release of von Willebrand factor (vWf) from human endothelial cells in vitro. 16) However, the effect of OxLDL on the activity of each blood coagulation factor in the blood coagulation pathway has been less well investigated.
In the present study, to clarify the effect of OxLDL in thrombogenicity of atherosclerotic plaques, we investigated the relationship between OxLDL and blood coagulation factors. Our results indicate that OxLDL binding of factor VIII, which is an essential component of the intrinsic pathway, affected the intrinsic pathway of the blood coagulation cascade.
MATERIALS AND METHODS
Preparation of LDL Human LDL (dϭ1.019-1.063 g/ml) was isolated by sequential ultracentrifugation from fresh plasma collected in EDTA as previously described. 17) The protein content of the LDL was assayed using the method of Lowry et al. with bovine serum albumin as the standard.
18)
Modification of LDL LDL was oxidized by incubation with 5 mM CuSO 4 in EDTA-free phosphate-buffered saline (PBS) at 37°C for specified time intervals at a protein concentration of 0.2 mg/ml. Acetylation of LDL (AcLDL) was performed by the method of Basu et al. 19) To prepare oxidized AcLDL (Ox-AcLDL), 0.2 mg/ml AcLDL was incubated for 24 h at 37°C with 5 mM CuSO 4 in EDTA-free PBS. Oxidation was arrested by refrigeration and the addition of Oxidatively modified low-density lipoprotein (OxLDL) is present in atherosclerotic lesions and has been proposed to play an important role in atherogenesis. Thrombosis is the major mechanism underlying acute complications of atherosclerosis. In the present study, we analyzed the interaction between OxLDL and blood coagulation factors, which are involved in the blood coagulation pathway. We investigated the effect of OxLDL on plasma coagulation by measuring prothrombin time (PT) as a parameter of the extrinsic pathway of blood coagulation and activated partial thromboplastin time (APTT) as a parameter of the intrinsic pathway of blood coagulation following the addition of OxLDL to plasma. OxLDL, but not native LDL, caused prolongation of APTT in a dose-and oxidation time-dependent manner. In addition, the oxidatively modified product of acetylated LDL (AcLDL), but not AcLDL, also caused prolongation of APTT. The inhibition of lysophosphatidylcholine production in OxLDL by phenylmethylsulfonyl fluoride or Pefabloc pretreatment of LDL resulted in a prolongation of APTT, which was equivalent to the effect of OxLDL. Moreover, OxLDL significantly inhibited blood coagulation factor VIII, IX, and XI activity. Furthermore, we demonstrated that recombinant factor VIII binds to OxLDL and that factor VIII associated with OxLDL is detected in the incubation mixture of OxLDL and plasma. These results indicate that the binding of factor VIII to OxLDL affects the intrinsic pathway of the blood coagulation cascade. The present study suggests that the interaction between OxLDL and factor VIII may provide important information on the initiation and progression of atherosclerosis.
300 mM EDTA and 25 mM butylated hydroxytoluene. To inactive the LDL-associated platelet-activating factor acetylhydrolase (PAF-AH), LDL (1 mg/ml) was preincubated with 6 mM phenylmethylsulfonyl fluoride (PMSF) 20) or 100 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (Pefabloc, Sigma, U.S.A.) 21) for 30 min at 37°C, and dialyzed against the PBS for 4 h at room temperature. PMSF-or Pefabloc-pretreated LDL (0.2 mg/ml) were oxidized by incubation with 5 mM CuSO 4 in EDTA-free PBS for 24 h at 37°C. The extent of oxidation was assessed by measuring the thiobarbituric acid reactive substances (TBARS) 22) and by the relative electrophoretic mobility (REM) in a 1% agarose gel compared with native LDL (Table 1) .
Assay and Extraction of Phospholipids from Chemically Modified LDLs Phospholipids from the chemically modified LDLs were extracted with chloroform/methanol (1 : 1). Two milliliters of chloroform and 2 ml of methanol were added to 2 mg of lipoprotein in a total volume of 1.8 ml of 10 mM PBS containing 0.01 M HCl. After vortex mixing for 10 s, the mixture was centrifuged at 1800ϫg for 10 min. The chloroform phase was collected and dried under a stream of N 2 . The dried lipids were redissolved in chloroform/methanol (2 : 1) and subjected to TLC on HPTLC plates (silica gel 60, Merck, Germany) using chloroform/ methanol/acetic acid/water (25 : 15 : 4 : 2). The bands on the TLC were visualized with primulin reagent (Wako Pure Chemical, Japan). The LysoPC and PC zones were scraped into test tubes and assayed for phosphorus content. The phospholipid levels were determined using a commercial kit (Wako Pure Chemical, Japan). The results of the phospholipids characterization of the chemically modified LDLs are depicted in Table 1 .
Coagulation Assays Plasma (Dade ® Ci-Trol ® Coagulation Control Level 1) purchased from Sysmex was diluted to 50% volume concentrations with LDL or chemically modified LDLs (final concentration of 100 mg/ml) and incubated for 5 min at 37°C prior to prothrombin time (PT) and activated partial thromboplastin time (APTT) assay. All coagulation tests were performed in a coagulometer (Behring Fibrintimer II, Sysmex, Japan).
For PT assay, 50 ml of the diluted plasma (with LDL or chemically modified LDLs) were incubated for 2 min at 37°C prior to the addition of 100 ml of PT reagent (Dade ® Thromboplastin · C Plus, Sysmex, Japan), and the time required for clot formation was determined. For APTT assay, 50 ml of the diluted plasma (with LDL or chemically modified LDLs) were incubated for 2 min at 37°C prior to the addition of 50 ml of APTT reagent (Dade ® Actin ® Activated Cephaloplastin Reagent, Sysmex, Japan). After a further 3 min, 50 ml of 20 mM CaCl 2 was added and the time required for clot formation was determined.
The activities of the coagulation factors were measured by using coagulation factor-deficient plasma. For the factor included in the extrinsic pathway (factor VII), PT reagent and the factor VII-deficient plasma was used. For the factors included in the intrinsic pathway (factor VIII, IX, XI and XII), APTT reagent and appropriate factor-deficient plasma were used. Twenty five microliters of the diluted plasma in the presence or absence of OxLDL was incubated with each factor-deficient plasma for 1 min at 37°C and the time required for clot formation of each sample was determined as described above. A calibration curve was prepared by diluting a standard human plasma (Sysmex), which was specified each coagulation factor activity, from 1-to 500-fold (factor VIII, IX, XI, XII activity, respectively) or 2000-fold (factor VII activity) with a Owren's veronal buffer (28 mM sodium barbital, 125 mM NaCl, pH 7.35) and the time required for clot formation was determined. The results were recorded on log-log graph paper with the clot formation time on the vertical axis and the activity of each coagulation factor horizontally, and calculated the activity of each coagulation factor in the samples. The activity of each sample was expressed as the percentage of the plasma without OxLDL of the control group.
Dissociation-Enhanced Lanthanide Fluorometric Immunoassay (DELFIA) OxLDL (0.02 pmol) was preincubated with 0.02 pmol of recombinant human factor VIII (American Diagnostica Inc., U.K.) in 100 ml of PBS for 1 h at 37°C. The binding assay of factor VIII to OxLDL was performed by DELFIA, utilizing lanthanide chelates and timeresolved fluorometry. 23, 24) Goat anti-human b-lipoprotein IgG fraction (1 mg/100 ml, Nippon Biotest Lab., Japan) were placed in wells of a 96-well microtiter plate and incubated for 12 h at 4°C. After removing the antibody fluid, the wells were blocked with PBS containing 0.5% gelatin for 1 h at 37°C. After washing the wells three times with PBS, the preincubation mixture of OxLDL and recombinant human factor VIII were reacted for 30 min at 37°C and then incubated with rabbit anti-human factor VIII polyclonal antibody (YLEM, Italy) (1 : 8000 diluted in PBS containing 0.1% gelatin) for 30 min at 37°C. This was followed by treatment with an Eu 3+ -labelled anti-rabbit antibody (Wallac Oy, Finland) (1 : 5000 diluted in PBS containing 0.1% gelatin) for 30 min at room temperature. Plates were washed six times and the bound Eu 3+ was dissociated and fluorescence enhanced by incubation with 100 ml of DELFIA enhancement solution (Wallac Oy, Finland). After shaking for 5 min, we determined fluorescence using a 1420 ARVOsx DELFIA Research Fluorometer (Wallac Oy, Finland) with the standard setting for Eu 3+ (excitation wavelength of 340 nm and an emission wavelength of 615 nm). In some experiments, LDL (1 mg) and OxLDL (1 mg) were preincubated with plasma (10 ml) in 100 ml of PBS for 15 min at 37°C, and then the binding assay of factor VIII in plasma to OxLDL was also performed.
Statistical Analysis Data were evaluated by paired Student's t-test. When the p value was less than 0.05, the difference was considered significant. 
RESULTS

Effects of LDL and OxLDL on Blood Coagulation
Assay The effect of OxLDL as well as LDL on in vitro coagulation assays (PT and APTT) was studied. Whereas LDL had no effect on PT and APTT, OxLDL significantly and substantially increased the time required for clot formation in APTT assay (Fig. 1) . The time required for clot formation in APTT assay by OxLDL was increased in a dose-dependent manner, whereas the time required for clot formation in the PT assay was slightly increased by OxLDL. When 100 mg/ml of OxLDL was incubated with plasma, APTT was increased 1.71-fold as compared with nonloaded OxLDL. The effect of OxLDL on the PT and APTT assays was similarly shown in an oxidation-time study. As the LDL oxidation progressed, the time required for clot formation in the APTT assay linearly increased, whereas PT slightly increased with oxidation time of LDL (Fig. 2) .
Effects of Chemically Modified LDLs on Blood Coagulation Assay
We next examined the effect of AcLDL and Ox-AcLDL on APTT assay. As shown in Fig. 3 , the time required for clot formation in APTT assay was increased 1.64-fold by Ox-AcLDL, whereas AcLDL had no effect. In addition, PMSF-and Pefabloc-pretreated OxLDL caused prolongation of APTT, which was equivalent to the effect of OxLDL (Fig. 3) .
Effect of OxLDL on the Activity of Various Blood Coagulation Factors
To investigate the suppression mechanism of OxLDL on the blood coagulation pathway, we examined the effect of OxLDL on the activity of the blood coagulation factors by PT and APTT assays using various coagulation factor-deficient plasmas. As shown in Fig. 4 , the activity of factors VIII, IX, and XI, which are responsible for the intrinsic pathway of blood coagulation, were suppressed by OxLDL (90.7%, 60.9%, and 67.7%, respectively). In particular, OxLDL markedly suppressed factor VIII activity. On the other hand, OxLDL did not affect factor VII, which is responsible for the extrinsic pathway of blood coagulation.
Binding of OxLDL to Blood Coagulation Factor VIII To clarify the interaction between OxLDL and factor VIII, binding analysis of factor VIII to OxLDL was examined by DELFIA. The reaction mixture of recombinant factor VIII and OxLDL was added to microtiter wells precoated with goat anti-human b-lipoprotein antibody. After extensive washing, the amount of the factor VIII-OxLDL complex remaining in the wells was determined using rabbit anti-human factor VIII polyclonal antibody and Eu 3+ -labelled anti-rabbit antibody. As shown in Fig. 5 , fluorescence intensity of the binding of factor VIII to OxLDL increased as LDL oxidation progressed and reached a plateau level at 4 h oxidation of LDL. This result suggests that incubation of various oxidized samples of LDL with factor VIII resulted in the formation of the OxLDL-factor VIII complex. Furthermore, we analyzed the interaction of OxLDL and factor VIII containing plasma by DELFIA. As shown in Fig. 6 , the incubation with OxLDL and plasma significantly increased the fluorescence intensity, while LDL had negligible effect. These results indicate that factor VIII binds to OxLDL.
DISCUSSION
The oxidative modification of LDL is associated with many changes in the chemical composition of LDL, including degradation of apolipoprotein B-100, generation of lipid peroxides and oxysterols, and conversion of PC to oxidized PC (OxPC) and LysoPC. 25) LysoPC is generated during LDL oxidation through enzymatic hydrolysis of PC by PAF-AH, an enzyme that is normally associated with LDL. 26) Treatment of LDL with PMSF or Pefabloc before oxidation inhibited LysoPC production but not TBARS production or the OxLDL electrophoretic mobility (Table 1) . In contrast, acetylation of LDL involves derivatization of lysine amino groups on LDL apolipoprotein B-100 without modification of lipid fraction. In the present study, we demonstrated that OxLDL, but not native LDL, caused prolongation of APTT in a doseand oxidation time-dependent manner (Figs. 1, 2 ). This effect was also shown for Ox-AcLDL, whereas AcLDL had no effect (Fig. 3) . In addition, PMSF-or Pefabloc-pretreated OxLDL caused prolongation of APTT, which was equivalent to the effect of OxLDL (Fig. 3) . Furthermore, factor VIII, IX, and XI activity were markedly inhibited by OxLDL (Fig.  4) . These results suggest that OxLDL affects the intrinsic pathway of blood coagulation via the inhibition of factor VIII, IX and XI activity in vitro, and the inhibition by OxLDL may be responsible for lipid peroxide, such as OxPC but not LysoPC, generation during LDL oxidation.
In the intrinsic pathway of blood coagulation, factor X activation, which participates in the conversion of a zymogen prothrombin into thrombin, the key enzyme of the coagulation cascade, 27) is provided by a membrane-bound Xase complex formed by activated factors VIII and IX. Thus, factor VIII is an essential component of the intrinsic pathway of blood coagulation. In plasma, factor VIII is bound to vWf, a glycoprotein that plays an essential role in hemostasis by promoting the attachment of platelets to the injured vessel wall. 28) It is also known that factor VIII levels in normal human plasma are approximately 1 nM. 29) On the other hand, the presence of OxLDL in the human circulation is supported by findings from several research groups who detected OxLDL in human plasma using immunological methods, 30, 31) and Itabe et al. reported that the mean OxLDL concentration in normal human plasma is approximately 0.1 ng/mg LDL protein. 30) In the present study, we demonstrated that recombinant factor VIII binds to OxLDL (Fig. 5) and factor VIII associated with OxLDL is detected in an incubation mixture of OxLDL and plasma (Fig. 6) . Therefore, the data presented here suggest that factor VIII is associated with OxLDL in the circulation. Although the relationship between the suppression of the intrinsic pathway by OxLDL and the thrombogenicity of atherosclerotic plaque is not clear, the interaction of OxLDL and factor VIII, at least in part, may be involved in the anti-thrombogenicity of blood vessel through suppression of factor VIII activity in circulation. However, in general, since the promotion of blood coagulation by OxLDL is well known to play an important role of the progression of atherosclerosis, increased thrombogenicity of atherosclerotic plaques in vivo may be attributed to the blood coagulation as activation of the upstream of extrinsic pathway based on endothelial dysfunction by the OxLDL that is newly generated in the atherosclerotic plaques, but not OxLDL in circulation, and the decrease of fibrinolytic activity in the circulating plasma. Further studies are needed to elucidate the issue.
In conclusion, we have shown that OxLDL affects the intrinsic pathway of blood coagulation, and its mechanism may be dependent on the binding of factor VIII to OxLDL. Further study on the interaction between OxLDL and factor VIII may provide important information on the initiation and progression of atherosclerosis.
